|
WO2006133196A1
|
|
Modulation of cholesteryl ester transfer protein (cetp) activity
|
|
EP1738763A1
|
|
Use of complement inhibitory proteins to treat spinal cord injury
|
|
JP2007008876A
|
|
Use of complement inhibitory protein for treating spinal cord injury
|
|
CA2508691A1
|
|
Use of complement inhibitory proteins to treat spinal cord injury
|
|
WO2005056769A2
|
|
Orally-administered live bacterial vaccines for plague
|
|
AU2003304255A1
|
|
Genetic marker for live bacterial vaccines
|
|
US6884866B2
|
|
Bulk drying and the effects of inducing bubble nucleation
|
|
AU2002322059A1
|
|
Improved vaccination against anthrax
|
|
US6846808B1
|
|
Plasmid-based vaccine for treating atherosclerosis
|
|
AU5531101A
|
|
Herpes virus complementing cell line
|
|
US6780405B1
|
|
Regulated antigen delivery system (RADS)
|
|
US6261573B1
|
|
Immunoadjuvants
|
|
US6207171B1
|
|
Polyphosphazene microspheres
|
|
EP1024825A1
|
|
Xenogeneic cholesteryl ester transfer protein (cetp) for modulation of cetp activity
|
|
US6376235B1
|
|
IVI-2, IVI-3 and IVI-4 loci of Enterococcus faecalis polynucleotide, polypeptides and method of use therefor
|
|
US6284533B1
|
|
Plasmid-based vaccine for treating atherosclerosis
|
|
AU2994697A
|
|
Plasmid-based vaccine for treating atherosclerosis
|
|
AU6314896A
|
|
Polyphosphazene polyelectrolyte immunoadjuvants
|
|
US6410022B1
|
|
Modulation of cholesteryl ester transfer protein (CETP) activity
|
|
US5958410A
|
|
Therapy of sarcoidosis
|
